Skip to content
The Policy VaultThe Policy Vault

Actimmune — Highmark

Severe Malignant Osteopetrosis (SMO)

Initial criteria

  • Diagnosis of severe, malignant osteopetrosis (SMO)
  • Prescriber attests the member will use Actimmune to delay the time to disease progression

Approval duration

12 months